Partha Basu, Head of the Early Detection, Prevention and Infections Branch at International Agency for Research on Cancer (IARC), shared a post on LinkedIn:
“New publication in the Int J Cancer based on a real-world study in China adds to the growing evidence supporting single-dose HPV vaccination.
Among girls aged 9-14 years, a single dose of the E. coli-produced HPV-16/18 vaccine generated strong neutralizing antibody responses, high antibody avidity, and memory B- and T-cell responses comparable to those induced by two doses at around 12 months post-vaccination. These findings further strengthen the scientific basis for single-dose HPV vaccination strategies and their potential to accelerate equitable access and progress toward the WHO goal of vaccinating 90% of girls against HPV.
International Agency for Research on Cancer (IARC) is thankful to the great collaborators at National Cancer Center, Chinese Academy of Medical Sciences, Beijing, China.”
Title: Memory Cell and Antibody Responses Following a Single Versus Two Doses of Escherichia coli-Produced Vaccine Against Human Papillomavirus Types 16 and 18: A Real-World Study in Chinese Girls
Authors: Tianmeng Wen, Li Dong, Jiayi Li, Yushu Feng, Lingling Nie, Zhongliang Li, Li Zhang, Shangying Hu, Weijin Huang, Fanghui Zhao, Partha Basu
Other articles featuring Partha Basu on OncoDaily.